An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ACRO (Association of Clinical Research Organizations) announced the election of Peyton Howell, Chief Operating & Growth Officer at Parexel, as Chair of the association effective Jan. 1, 2024. Lisa Moneymaker, Chief Technology Officer & Chief Product Officer at Saama, was elected Vice Chair. Mike Crowley, Chief Administrative Officer & General Counsel at Parexel, was elected Secretary, and Ari Feldman, Senior Vice President, Global Compliance and Strategy at Medidata Solutions, was re-elected Treasurer. ACRO also welcomed Advarra and YPrime as its newest members, reflecting the association's continued evolution in representing CROs and clinical technology companies that support drug development.
Positive
None.
Negative
None.
WASHINGTON--(BUSINESS WIRE)--
ACRO today announced that its Board of Directors has elected Peyton Howell, Chief Operating & Growth Officer at Parexel, as Chair of the association effective Jan. 1, 2024. Lisa Moneymaker, Chief Technology Officer & Chief Product Officer at Saama, was elected Vice Chair. In addition, the Board of Directors elected Mike Crowley, Chief Administrative Officer & General Counsel at Parexel, as Secretary of the association and re-elected Ari Feldman, Senior Vice President, Global Compliance and Strategy at Medidata Solutions, as Treasurer.
Ms. Howell joined Parexel in 2018 and most recently was President, Consulting and Chief Commercial & Strategy Officer leading the company to record new business growth and creation of a patient-focused strategy. She has more than 25 years of leadership experience in the healthcare industry and prior to joining Parexel held several leadership positions with AmerisourceBergen — now Cencora (a Fortune 20 company) — most recently as President for Health Systems and Specialty Care Solutions, a $50B business unit. Ms. Howell was a founder of Lash Group, growing the company from an early innovator of patient access services to nearly 5,000 employees and serving as President for nearly 10 years following its acquisition by AmerisourceBergen. She holds a Masters’ in Healthcare Administration (MHA) from The Ohio State University and in 2020 was named a Luminary by the Healthcare Businesswomen’s Association (HBA). Ms. Howell serves on the Board of Directors of Tandem Diabetes Care (NASDAQ: TNDM), a medical device manufacturer, and has represented Parexel on the ACRO Board since 2020.
“Across a challenging geopolitical and economic climate in 2023 ACRO member companies maintained their focus on the patient, adapting and innovating to drive continued transformation in the conduct of clinical trials,” said Ms. Howell. “I am excited to lead the association in the year ahead and to build on this progress as we foster deeper connections and collaboration across the clinical research enterprise to optimize the development of new therapies for patients around the world.”
ACRO is also pleased to announce the addition of Advarra, a site-centric technology company. and YPrime, an eClinical trial management solutions company, as its newest members.
“The addition of YPrime and Advarra to ACRO’s membership reflects ACRO’s continued evolution in representing the CROs and clinical technology companies that support drug development,” said Ms. Moneymaker. “Initiatives like ACRO’s newly formed AI/ML Committee highlight the value of providing a space for leaders from across the clinical research industry to collaborate on the topics that are driving industry change.”
About ACRO
ACRO advocates as the collective voice of innovative clinical research and technology organizations to regulators and policymakers, educating stakeholders and shaping policies that foster the efficient, effective and safe conduct of clinical research.
tandem diabetes care, inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. the company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. tandem manufactures and sells the t:slim x2™ insulin pump, the only pump capable of remote feature updates using a personal computer, and the t:flex® insulin pump, the first pump designed for people with greater insulin requirements. tandem is based in san diego, california. safety information please note that this account is not intended to be used for product support or medical advice. if you are having a medical emergency, please dial 911. if you are having an issue with one of our products and need immediate assistance, please call our 24 hour customer support team at 877-801-6901 and press 1 twice. tandem insulin pumps are intended for the subcutan